What Is a Continuous Glucose Monitor?
A continuous glucose monitor (CGM) is a wearable device that measures blood sugar levels in real time — every 1–5 minutes — through a small sensor placed just under the skin, typically on the arm or abdomen. Unlike fingerstick testing, which captures a single moment, a CGM shows you a continuous glucose curve: where your blood sugar is, where it’s been, and which direction it’s heading.
Most CGMs send readings wirelessly to a smartphone app or dedicated receiver, with alarms when glucose goes too high or too low. Some are approved to replace fingerstick testing entirely; others are used alongside it.
What CGMs Add for Type 2 Diabetes
For people with Type 2 diabetes, CGMs offer several advantages that a traditional glucometer cannot provide:
| CGM Benefit | What It Reveals |
|---|---|
| Post-meal glucose patterns | Exactly how different foods affect your blood sugar — within hours of eating |
| Time in range (TIR) | What percentage of the day glucose stays between 70–180 mg/dL — a more complete picture than A1C alone |
| Overnight trends | Dawn phenomenon, nocturnal hypoglycemia, or simply how glucose behaves while you sleep |
| Exercise response | How aerobic vs. resistance exercise affects glucose in real time |
| Hypoglycemia alerts | Alarms 15–30 minutes before glucose drops to dangerous levels |
| Behavioral feedback | Seeing glucose data tied to specific meals or activities is highly motivating for lifestyle change |
CGM Options for Type 2 Diabetes
Several CGMs are currently available in the US. The right choice depends on wear duration, whether you need real-time alerts, and insurance coverage.
| Device | Wear Duration | Real-Time Alerts | Notes |
|---|---|---|---|
| Dexcom G7 | 10 days | Yes | Most widely used; integrates with AID systems; FDA-cleared for T2D on insulin |
| Abbott FreeStyle Libre 3 | 14 days | Yes (Libre 3) | Smallest sensor; no fingerstick needed; broad T2D coverage |
| Medtronic Guardian 4 | 7 days | Yes | Integrates with Medtronic insulin pumps |
| Senseonics Eversense E3 | Up to 180 days (implantable) | Yes | Implanted by a provider; longest wear duration; daily calibration required |
The Senseonics/Sequel Med Tech partnership is developing a next-generation 1-year implantable CGM integrated with automated insulin delivery — specifically targeting the Type 2 diabetes population who would benefit most from reduced device burden.
Who with Type 2 Diabetes Should Use a CGM?
The ADA’s 2024 Standards of Care recommend CGM use for all people with diabetes who use insulin. Increasingly, CGMs are also being recommended for people with Type 2 diabetes who are not on insulin, particularly those with an A1C above 7% or who want to understand their glucose patterns better.
CGMs are most impactful for:
- People on insulin who want to reduce fingerstick burden
- Anyone experiencing hypoglycemia or unaware hypoglycemia
- People wanting real-time feedback on how food and exercise affect blood sugar
- Those with variable A1C who want to understand what’s driving it
Coverage: Is a CGM Covered by Insurance?
Coverage has expanded significantly in recent years:
- Medicare: Covers CGMs for people with diabetes who use insulin. Since 2023, Medicare coverage has expanded and no longer requires multiple daily insulin injections as a prerequisite.
- Medicaid: Coverage varies by state but has been expanding.
- Commercial insurance: Most major plans cover CGMs for people on insulin; coverage for non-insulin T2D users is growing but inconsistent.
- Out of pocket: FreeStyle Libre is available over the counter at many pharmacies; cost is roughly $40–75 per sensor (14-day supply) without insurance.
If you’re unsure about coverage, ask your doctor’s office to submit a prior authorization — the process is routine. A CGM paired with thoughtful lifestyle changes can produce meaningful A1C improvements that justify the cost.
Related Articles
- Automated Insulin Delivery (AID) Systems for Type 2 Diabetes
- Artificial Intelligence and Type 2 Diabetes: From Prevention to Daily Management
This article is for informational purposes only and does not constitute medical advice. Always discuss device options with your healthcare provider.
Sources & Further Reading
- ADA Standards of Care: Diabetes Technology (2024) — American Diabetes Association
- Continuous Glucose Monitoring — NIDDK
- Continuous Glucose Monitoring Devices — U.S. FDA
- CGMs for People with Diabetes — diabetes.org
- Medicare Coverage of CGMs — CMS
Pingback: Continuous Glucose Monitoring Explained: How CGM Works, What It Shows, and Who Needs It - abcsofa1c.com